TO: ALL PRINCIPAL INVESTIGATORS, NURSES, AND DATA MANAGERS

FROM: NRG-DT001 Study Chair
Meng Welliver, MD, PhD

DATE: November 18, 2021

RE: PROTOCOL NRG-DT001 – Cohort A, Permanently Closed to Accrual

Cohort A (All Dose Levels) Permanently Closed to Accrual
Cohort A (extremity/body wall) of NRG-DT001, “A Phase IB Trial of Neoadjuvant AMG 232 (KRT-232) Concurrent with Preoperative Radiotherapy in Wild-Type p53 Soft Tissue Sarcoma (STS),” is permanently closed to accrual effectively immediately because the protocol-specified number of patients enrolled at the dose expansion cohort have completed the DLT observation period. (Cohort A was temporarily closed to accrual on September 10, 2021 to allow for DLT monitoring prior to making a reopening or permanent closure decision.)

Note: Cohort B (abdomen/pelvis/retroperitoneum) remains open to accrual to Dose Level 2.

Please distribute this information to the appropriate personnel.